The Gut Microbiota in Immune-Mediated Inflammatory Diseases

Jessica D. Forbes1,2, Gary Van Domselaar1,2 and Charles N. Bernstein3*

1 Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada, 2 National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, 3 Department of Internal Medicine and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, MB, Canada

The collection of microbes and their genes that exist within and on the human body, collectively known as the microbiome has emerged as a principal factor in human health and disease. Humans and microbes have established a symbiotic association over time, and perturbations in this association have been linked to several immune-mediated inflammatory diseases (IMID) including inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis. IMID is a term used to describe a group of chronic, highly disabling diseases that affect different organ systems. Though a cornerstone commonality between IMID is the idiopathic nature of disease, a considerable portion of their pathobiology overlaps including epidemiological co-occurrence, genetic susceptibility loci and environmental risk factors. At present, it is clear that persons with an IMID are at an increased risk for developing comorbidities, including additional IMID. Advancements in sequencing technologies and a parallel explosion of 16S rDNA and metagenomics community profiling studies have allowed for the characterization of microbiomes throughout the human body including the gut, in a myriad of human diseases and in health. The main challenge now is to determine if alterations of gut flora are common between IMID or, if particular changes in the gut community are in fact specific to a single disease. Herein, we review and discuss the relationships between the gut microbiota and IMID.

Keywords: microbiome, systems microbiology, chronic immune mediated inflammatory diseases, metagenome, dysbiosis

INTRODUCTION

Immune-mediated inflammatory disease (IMID) is a term used to define a group of clinically heterogeneous, ostensibly unrelated disorders that are recognized to share common pathogenic mechanisms. Most IMID are highly prevalent in well-developed industrialized countries; in Western populations the prevalence of IMID is approximately 5–8% (Bayry and Radstake, 2013) and encompasses over 100 different clinical diseases including inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and psoriasis/psoriatic arthritis.

Knowledge of the etiopathogenic mechanisms of IMID remains limited but these diseases are thought to arise secondary to a complex interplay between environmental and genetic factors. The rise in IMID prevalence in developed countries in the latter half of the 20th century...
implies that environmental determinants play a significant role in disease onset. Numerous environmental factors have been proposed to be important in the emergence of IMID including hygiene, socioeconomic status, cigarette smoking, diet, antibiotic usage, vitamin D, hormones, appendectomy, excess alcohol, and microbial exposure (Ananthakrishnan, 2015; Belbasis et al., 2015), but whether any of these factors are causal in IMID has yet to be established.

Immune-mediated inflammatory disease also share a considerable portion of their heritable etiology. This is evident through familial clustering of multiple IMID, epidemiological co-occurrence and a similar efficacy of therapeutics directed at specific biologic loci across some diseases (Somers et al., 2006; Diaz-Gallo and Martin, 2012), which taken together, suggest that genetic factors predispose persons to IMID. The best-known genetic factor of IMID is the human leukocyte antigen (HLA) haplotypes (Wu et al., 2015). Moreover, genome-wide association studies have identified associations with more than 200 rare or common non-HLA variants (Wu et al., 2015) although known allelic variants account for a relatively low risk explaining 20–50% of disease heritability (Parkes et al., 2013; Sorrentino, 2014).

**IMMUNE-MEDIATED INFLAMMATORY DISEASE COMORBIDITY**

Immune-mediated inflammatory disease are defined by the principle organ system that is affected [the gastrointestinal tract in IBD, the synovium in RA and the central nervous system (CNS) in MS]; however, they are associated with comorbidities that extend beyond the primary target organ. In this regard, comorbidities that present in persons with IMID greatly contribute to the burden of disease and quality of life. IBD for example, frequently manifests with extra-intestinal complications in up to 50% of cases and covers a broad clinical spectrum affecting nearly every organ system (Harbord et al., 2016). Erythema nodosum and pyoderma gangrenosum of skin, ocular uveitis and episcleritis, primary sclerosing cholangitis, and arthritides, such as pauciarticular and polyarticular peripheral arthritis and seronegative spondyloarthropathy are among the more common extra-intestinal diseases that may coexist in IBD (Harbord et al., 2016). Rarely, a number of neurological complications including peripheral neuropathy, myopathy, and demyelinating disorders may occur in persons with IBD. Comorbidities are not specific to IBD; persons with other IMID often present with a number of additional clinical disorders including risks for osteoporosis, venous thromboembolic disease and ischemic heart disease (Bernstein et al., 2000, 2001a, 2008).

It is well established that in comparison to the general population, IMID patients are at greater risk for the development of another IMID-related condition. Weng et al. (2007) examined the co-occurrence of IBD with other IMID (asthma, psoriasis, type 1 diabetes (T1D), RA, MS, SLE, vitiligo, autoimmune thyroiditis, and chronic glomerulonephritis). The authors reported 17% of IBD patients and 10% of persons without IBD were diagnosed with at least one additional IMID. Persons with IBD had significantly increased odds pertaining to the development of asthma [odds ratio; OR 1.5, 95% confidence interval (CI) 1.4–1.6], psoriasis (OR 1.7, 95% CI 1.5–2.0), RA (OR 1.9, 95% CI 1.5–2.3), and MS (OR 2.3 95% CI 1.6–3.3). These results have been corroborated by other studies that add further credence to the validity of the phenomenon of IMID co-occurrence (Bernstein et al., 2001b, 2005; Cucino and Sonnenberg, 2001; Cohen et al., 2008; Marin-Jimenez et al., 2014; Vanaclocha et al., 2015).

An idiopathic etiology represents a pivotal commonality of IMID, though the clinical, epidemiological, genetic, and environmental links between IMID combined with the preeminent association between IBD and the gut microbiome has laid the foundation for studies evaluating the gut microbiome in IMID. Intriguingly, recent research suggests there are striking findings to support the gut microbiome as playing an important function in the etiopathogenesis of several IMID. Herein, we will review the current state of the knowledge regarding changes in the gut microbiome of the more common IMID, including IBD, MS, RA, AS, SLE, psoriasis, and psoriatic arthritis.

**GUT MICROBIOME: AN OVERVIEW**

Knowledge of the role of commensal microbes that inhabit mucosal surfaces of the human body and their role in health and disease is increasing at a remarkable rate. The term “microbiota” refers to the population of microbes at a particular anatomical niche and “microbiome” refers to the collective genes encoded by all microbes of that particular niche. The human gastrointestinal tract comprises approximately 10^{14} bacterial microbes and amounts to a biomass of approximately 2 kg (Qin et al., 2010). It has been assumed for some time that there are roughly 10 times as many microbes as there are eukaryotic cells in the human body, but recent support proposes the ratio for microbial to human cells is 1.3:1 (Abbott, 2016). The bacteria of the gut belong to more than 1000 different species encoding more than 3 million bacterial genes (microbiome) exceeding the number encoded by the human genome by 150-fold (Qin et al., 2010).

The study of the gut microbiome cannot be separated from its environmental context; host genetics, nutrition, the environment, geographical location, early microbial exposures, and other factors profoundly impact the microbiome of the healthy human gut. Extensive sampling of the human microbiome has revealed that although the diversity and abundance of microbial communities of particular niches vary widely both within and among individuals (Huttenhower et al., 2012), the functional repertoire of the healthy microbiome, including the gut, is relatively stable regardless of the microbe composition. A microbiome becomes more stable in adulthood, which subsequently changes in the elderly (Claesson et al., 2012). However, there are temporal variations within a healthy individual’s microbiome that can occur even over a short period of time (David et al., 2014).

The healthy human gut is dominated by the presence of four bacterial phyla: Bacteroidetes, Firmicutes, Actinobacteria,
and Proteobacteria with Bacteroidetes and Firmicutes accounting for a large majority of endemic bacteria in the gut (Tap et al., 2009). Within the healthy human gut, the phylum Firmicutes are divided into two major classes of Gram-positive bacteria: Bacilli and Clostridia (primarily Clostridium cluster IV and Clostridium XIVa). The Bacteroidetes are Gram-negative bacteria, of which the Bacteroides represents one of the most abundant genera in the gut (Huttenhower et al., 2012). Considerable diversity of bacterial species exist within a normal gut; recent studies have recognized common core subsets within the microbiome that are relatively stable throughout large populations and that can even persist in an individuals’ gut for their entire adult life (Faith et al., 2013).

There is a clear spatial distribution of microbes within the gastrointestinal tract with diversity increasing from the stomach to the colon, and it is at the terminal ileum where prevalent species change from aerobes to anaerobes (Mondot et al., 2013). Within the gut itself, there is a significant difference in microbial populations on mucosal surfaces compared to within the lumen (Li et al., 2015). Microbes at the mucosal surface are in closer proximity to the intestinal epithelium and may have a greater influence on the immune system whereas luminal/fecal microbes might be more essential for energy and metabolic interactions. This is relevant since many studies of the gut microbiota use fecal material for community profiling and thus may not adequately reflect the totality of viable microbes within the gut.

Under normal physiological conditions, the human gut microbiota is a homeostatic ecosystem with several vital functions and interrelationships important to host health including food digestion, development of the host immune system and intestinal epithelial barrier and protection against pathogens (Shreiner et al., 2015). Disruption of this equilibrium can result in dysbiosis and increase risk of disease. Gut dysbiosis refers to an altered composition of intestinal microbial populations and is thought to provide continuous immunological stimulation leading to immune response anomalies in numerous IMID. Altered community composition has been established in a number of gastrointestinal diseases: IBD, celiac disease, irritable bowel syndrome, functional dyspepsia, antibiotic-associated diarrhea, tropical enteropathy, and others (Brown et al., 2015; Keely et al., 2015; D’Argenio et al., 2016; Distrutti et al., 2016; Larcombe et al., 2016). Accumulating evidence proposes that dysbiosis of the intestinal microbiota is not limited to gastrointestinal diseases thereby suggesting that gut bacteria can affect the systemic immunological response. A number of studies have investigated gut dysbiosis in relation to obesity, diabetes, chronic periodontitis, vaginosis, atopic diseases, non-alcoholic steatohepatitis, Alzheimer’s disease, and others (Daulatzai, 2014; Adams and Morrison, 2016; Blasco-baque et al., 2016; Johnson and Ownby, 2016). While a breakdown in the equilibrium of the intestinal milieu may be widely recognized, perturbations surrounding biological mechanisms driving dysbiosis exist and it is unclear whether dysbiosis manifests as a cause or consequence of disease.

MICROBIOME AND IMMUNITY LINK

The link between the gut microbiome and host immunity involves a bidirectional relationship between microbes and the host innate and adaptive immune system. The balance between pro- and anti-inflammatory mechanisms is critical for gut immune homeostasis and is directly affected by the commensal microbial communities of the gut. For example, in mice, segmented filamentous bacteria (SFB) promote the accumulation of pro-inflammatory T helper 1 (Th1) and Th17 cells in the small intestine (Gaboriau-Routhiau et al., 2009). Anti-inflammatory responses are facilitated by the generation of regulatory T cells (Treg cells) through short-chain fatty acid (SCFA) production (Arpaia et al., 2013). Similarly, studies report retinoic acid (Mucida et al., 2007), bacteria belonging to the Clostridium cluster IV and XIVa (Atarashi et al., 2013), polysaccharide A of Bacteroides fragilis (Round and Mazmanian, 2010) and Faecalibacterium prausnitzii (Qiu et al., 2013) to promote the accumulation of Treg cells. Hence, microbes and metabolites in the gut are essential in maintaining immunological equilibrium. And it is suspected that perturbations of the gut microbiota disrupt this balance primarily affecting the gut mucosa and also the systemic immune response. A ‘leaky gut’ characterized by increased gut permeability, microbial imbalance, and impaired mucosal immunity has been identified to precede the development of IMID. Figure 1 shows a schematic illustration of the interaction between the immune system and gut microbiota in IMID.

GUT MICROBIOTA IN IMMUNE-MEDIATED INFLAMMATORY DISEASES

Inflammatory Bowel Disease (IBD)

The two main clinical phenotypes of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). CD is a transmural disease characterized by deep ulcerations distributed in a skipped pattern that can affect the gastrointestinal tract anywhere from the mouth to the anus, though the terminal ileum is most frequently affected. In contrast, UC demonstrates continuous, superficial inflammation (of the mucosa and submucosa) involving the rectum and extending proximally to the cecum.

At present, not only have numerous candidate pathogens (adherent invasive E. coli (AIEC), Bacteroides fragilis, Clostridium difficile, Mycobacterium avium ssp. paratuberculosis, Yersinia enterocolitica, Listeria monocytogenes, Salmonella, Campylobacter) been implicated in disease onset and/or perpetuation (Becker et al., 2015), but over 400 complex microbiome surveys have been conducted to identify the totality of microbes in the IBD gut and precisely how the IBD gut differs from that of a healthy person. Indeed, advances in culture-independent sequencing and bioinformatics analyses in recent years have provided tremendous insight into the structure and function of the gut microbiota. Though patterns of gut dysbiosis are inconsistent among published studies, partly owing to specimen type (stool versus biopsy) or analysis methods,
Forbes et al. The Gut Microbiota in Immune-Mediated Inflammatory Diseases

FIGURE 1 | Role of the gut microbiome in the pathogenesis of IMID.

Enterocytes (via recognition of microbe-associated molecular patterns by Toll-like receptors) and M cells (transcytosis) communicate microbial dysbiosis to the mucosal immune system. Gut dysbiosis, in combination with a reduction of SCFA can shift the Treg-Th17 balance toward inflammation through Th17 expansion. Several pro-inflammatory cytokines are released in the lamina propria (LP) including IL-6, IL-17, IL-21, IL-23, and IFN-γ. The inflammatory state enhances intestinal permeability through expression of tight junction proteins including occludins and claudins and may lead to microbial translocation and enhanced antigen exposure in the LP. Activated T cells, B cells and dendritic cells (DC) travel to the mesenteric lymph nodes (MLN) via lymphatic vessels. Antigen presentation by DCs to T cells occurs and B cells differentiate toward plasma cells. Activated B cells, Th17 cells, and antibody-producing plasma cells enter circulation. B cells may be stimulated to differentiate toward autoantibody producing plasma cells if exposed to mimicry antigen in LP or MLN. Increased Th17 cells and presence of autoantibodies are the result of the microbiota induced pro-inflammatory state. Figure adapted from van der Meulen et al. (2016) with permission and modified.

studies surveying the gut microbiome in persons with IBD have consistently demonstrated perturbations of the structure and function of the microbiome.

Studies frequently document an overall reduction of diversity, the total number of species in a community. In fact, data from the MetaHIT consortium suggest that persons with IBD harbor on average 25% fewer microbial genes than healthy persons (Qin et al., 2010). Diversity is reduced in the fecal and mucosal microbiomes of IBD (Manichanh et al., 2006; Lepage et al., 2011) and has also been documented among monozygotic twins discordant for CD (Dicksveld et al., 2008). Decreased diversity has been attributed to shifts in the abundance of the Firmicutes, and more specifically the Clostridium leptum and C. coccoides group (Manichanh et al., 2006). Likewise, utilizing a custom phylogenetic microarray Kang et al. (2010) reported some bacteria belonging to the Firmicutes phylum including Eubacterium rectale of the Lachnospiraceae and Ruminococcus albus, R. callidus, R. bromii, and F. prausnitzii of the Ruminococcaceae were 5- to 10-fold more abundant in healthy persons compared to CD.

The gut microbiome was recently characterized according to the three most dominant phenotypes of CD: inflammation of the colon, the terminal ileum, or both (Table 1) (Naftali et al., 2016). The authors demonstrated ileal and colonic CD sustain distinct microbiome patterns. For example, ileal CD samples were richer in Escherichia (Enterobacteriaceae) and disease activity correlated with Fusobacterium abundance whereas colonic CD had higher levels of Faecalibacterium and two unidentified genera of the Clostridiales and Ruminococcaceae. The variance in CD microbiome patterns suggests that different mechanisms might underlie the two major clinical manifestations of CD. Recently, de Meij et al. (2015) described the gut microbiome composition in active new-onset pediatric CD compared with 3 months following initiation of treatment. At baseline, a greater diversity of Proteobacteria and a lower abundance of Bacteroidetes were observed in CD compared to controls. And upon clinical remission, the microbiota profile of CD seemed to shift to a profile similar to the control population.

The largest study to date related to the mucosal-associated microbiota and new-onset CD conducted by Gevers et al. (2014) included 468 children and adolescents (<17 years) with newly diagnosed CD and a control group of 229 persons with non-inflammatory conditions of the gastrointestinal tract. Mucosal and fecal samples were obtained prior to the initiation of treatment in subjects with a spectrum of disease phenotypes based on severity, location (terminal ileum and rectum) and behavior. Overall, disease status strongly correlated to increases in the Gut Microbiota in Immune-Mediated Inflammatory Diseases.
### TABLE 1 | Current studies investigating the role of the gut microbiota in IMID patients.

| IMID         | Subjects                                                                 | Comments                                                                                                                                                                                                 | Reference                                      |
|--------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| IBD          | Thirty-one patients with ileal, ileocolic, and colon-restricted CD        | Distinct microbiota profiles observed between ileal and colonic CD: ileal CD richer in *Escherichia* and disease activity correlated with abundance of *Fusobacterium*; increased abundance of *Faecalibacterium*, *Clostridiales*, and *Ruminococcaceae* in colonic CD. | Nafatali et al., 2016                          |
|              | Sixty newly diagnosed pediatric CD                                         | Increased diversity of Proteobacteria and decreased abundance of Bacteroidetes in CD at baseline. Microbiota profile of CD resembled profile of controls upon clinical remission. | de Meij et al., 2015                           |
|              | Four hundred and sixty-eight newly diagnosed pediatric CD                 | Increased abundance of Enterobacteriaceae, Pasteurellaceae, *Vibrio*, *Bacteroides*, *Fusobacteriaceae* and decreased abundance of *Erysipelotrichales*, *Bacteroidales*, and *Clostridiales* correlates with disease status. Shifts more strongly observed in tissue versus stool. | Gevers et al., 2014                            |
|              | Fifteen patients with CD, 21 patients with UC                             | Bacteroidetes and Fusobacteria more abundant in inflamed CD mucosa versus inflamed UC. *Proteobacteria* and *Firmicutes* more abundant in inflamed UC mucosa. *Faecalibacterium*, *Bacteroidetes*, and *Pseudomonas* levels differ between inflamed CD and UC; 13 genera significantly differed within the non-inflamed mucosa. Non-inflamed UC mucosa most different from non-IBD mucosa. No variation in taxa when comparing different gut compartments within CD or UC. | Forbes et al., 2016                            |
| MS           | Seven RRMS patients                                                       | Differences in *Firmicutes*, Bacteroidetes, and *Proteobacteria*. *Faecalibacterium* decreased in MS. Differences in *Bacteroidaceae*, *Faecalibacterium*, *Ruminococcaceae*, and *Lachnospiraceae* and other *Clostridiales* in *glattiramer* acetate-treated patients compared to untreated. Vitamin D associated with changes in *Firmicutes*, *Actinobacteria*, and *Proteobacteria*. Untreated patients had increase in *Akkermansia*, *Faecalibacterium*, and *Coprococcus* after vitamin D treatment. | Mowry et al., 2012                             |
|              | Fifty-three MS patients: 22 untreated; 13 *glattiramer* acetate treated; 18 IFN-β treated | Increased *Methanobrevibacter smithii* in MS. Decreased *Butyrivirgatus* and *Lachnospiraceae* in untreated MS.                                                                                       | Jhangi et al., 2014                            |
|              | Twenty pediatric RRMS                                                     | Increased *Escherichia*, *Shigella*, *Clostridium*. Decreased *Eubacterium rectale*, *Corynebacterium*.                                                                                                  | Tremlett et al., 2015                           |
|              | Fifteen pediatric RRMS                                                   | IL-17+ T cells positively correlated with overall richness and evenness; inverse correlation between IL-17+ T cells and Bacteroidetes                                                                     | Tremlett et al., 2016a                          |
|              | Seventeen pediatric RRMS                                                 | Decreased *Fusobacteria*, increased *Firmicutes* and *Euryarchaeota* linked to shorter relapse time.                                                                                                     | Tremlett et al., 2016b                          |
| RA           | Fifty-one early (<6 mo) RA                                               | Decreased bifidobacteria, *Bacteroides fragilis* subgroup, *Eubacterium rectale*–*Clostridium cocoides* subgroup, and Bacteroides–Porphyromonas–Prevotella groups | Vahttovuo et al., 2008                         |
|              | Fifteen early (<6 mo) RA                                                 | Increased *Lactobacillus* and diversity.                                                                                                                                                                  | Liu et al., 2013                                |
|              | Forty-four new-onset RA: 26 chronic, treated RA; 16 PsA                  | Increased *Prevotella copri* in NORA; decreased *Bacteroides* and beneficial microbes.                                                                                                                  | Sher et al., 2013                               |
|              | Seventy-seven treatment naïve RA; 17 treatment naïve RA paired with healthy relatives; 21 DMARD-treated RA | Increased *Lactobacillus salivarius*; decreased *Haemophilus*; Metagenomic linkage groups containing *Clostridium asparagiforumes*, *Gordonibacter pamelaeae*, *Eggerthella lenta*, *Lachnospiraceae*, *Bilophobacterium dentium*, *Lactobacillus sp.*, and *Ruminococcus lactaris* enriched. | Zhang et al., 2015                              |
|              | Forty RA                                                                  | Expansion of *Actinobacteria* (*Eggerthella, Actinomyces*), *Turicibacter*, *Streptococcus*. Reduced *Faecalibacterium*. *Collinsella* correlated with high levels of alpha-aminoacid acid and asparagine and IL-17A production. Role of *Collinsella* in altering gut permeability and disease severity confirmed in experimental arthritis. | Chen et al., 2016                               |
| AS           | Fifteen AS patients                                                       | Increased prevalence of sulfate-reducing bacteria. Decreased immunological tolerance to *Bacteroides*.                                                                                                   | Stebbings et al., 2002                          |
|              | Nine recent-onset (<48 mo) TNF-inhibitor naïve AS patients               | Increased diversity, *Lachnospiraceae*, *Ruminococcaceae*, *Rikenellaceae*, *Porphyromonadaceae*, and *Bacteroidaceae*; decreased *Veillonellaceae* and *Prevotellaceae* | Costello et al., 2015                           |

(Continued)
in the abundance of the Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae and a decrease in the abundance of Erysipelotrichales, Bacteroidales, and Clostridiales. Importantly, the alterations described were more strongly observed in tissue samples with weaker correlations observed in stool, implying a less dramatic shift in the luminal microbiota regardless of disease presence. The authors also demonstrated that microbiota profiles at time of diagnosis could be predictive for future disease outcomes; abundant levels of Fusobacterium could be predictive for future disease outcomes; abundant microbiota regardless of disease presence. The authors also demonstrated that microbiota profiles at time of diagnosis could be predictive for future disease outcomes; abundant levels of *Fusobacterium* and *Haemophilus* positively correlated with the pediatric CD activity index whereas levels of Enterobacteriaceae were negatively correlated. Furthermore, the microbiome composition between terminal ileal and rectal mucosal specimens were determined to be less different than differences observed between tissue and stool. Our group has recently reported similar observations of a somewhat homogenous gastrointestinal tract (using mucosal biopsies from the ileum, cecum, mid-colon, and rectum) in terms of microbe content and abundance within CD and UC cohorts (Forbes et al., 2016). We also explored the presence and absence of inflammation as an influencing factor on microbiome composition; shifts in microbe abundance comparing the inflamed mucosa between CD and UC were observed but these shifts were more dramatic in the non-inflamed mucosa between CD and UC.

### Microbes Enriched or Reduced in Inflammatory Bowel Disease

*Bacteroides* is the most dominant genus in Western microbiotas and can both positively and negatively affect the host (Wexler, 2007). Generally, while the overall abundance of the order Bacteroidales is increased in IBD, in certain circumstances particular species may be reduced; *Parabacteroides distasonis* is significantly decreased in inflamed IBD mucosa (Zitomersky et al., 2013). Pathogenic bacteria including *E. coli*, and *Shigella*, and others such as *Rhodococcus* and *Stenotrophomonas maltophilia* are increasingly observed in IBD (Knösel et al., 2005; Guerrero et al., 2015; Jensen et al., 2015). Other pathogens both with potential roles in the disease course include *Prevotellaceae, C. difficile, Klebsiella pneumoniae, Proteus mirabilis*, and *Helicobacter hepaticus*.

The relative abundance of the Enterobacteriaceae in persons with IBD (Kolho et al., 2015) and mouse models of IBD (Nagao-Kitamoto et al., 2016) is increased. Much research has focused on the role of *E. coli*, specifically AIEC, in IBD etiology; AIEC strains have been isolated from ileal-involving CD tissue (Darfeuille-Michaud et al., 2004) and the genera *Escherichia* and *Shigella* (indistinguishable by 16S analysis) are highly enriched in patients with IBD and this enrichment was more pronounced in mucosal samples versus stool samples (Petersen et al., 2015). It has also recently been demonstrated that a Western diet induces a shift in microbiome composition increasing the susceptibility to AIEC infection (Agus et al., 2016). AIEC possess the capability to invade enterocytes, replicate within macrophages and induce granuloma formation *in vitro* (Martínez-Medina and García-Gil, 2014), and though AIEC strains may be present within a healthy gut, they do not have the ability to adhere to ileal enterocytes. Therefore, colonization of the inflamed ileum provides a preferential environment for these microbes to influence the disease course. It has also been shown that the anti-inflammatory drug, mesalamine, used for IBD therapy, decreases gut inflammation and correlates with a reduction of *Escherichia/Shigella* abundance (Morgan et al., 2012).

*Fusobacterium* species are members of the normal oral and gut microbiota in humans; however, particular species (adherent, invasive, pro-inflammatory) are recognized as opportunistic pathogens in CD and UC. The relative abundance of *Fusobacterium* is increased in mouse models and the colonic mucosa of IBD; Strauss et al. (2011) isolated *Fusobacterium* species from 63.6% of patients with IBD versus 26.5% of healthy controls. Moreover, 69% of all *Fusobacterium* isolated from IBD patients were identified as *F. nucleatum* and strains isolated from the inflamed mucosa were more invasive in a Caco-2 cell invasion assay than strains isolated from the healthy mucosa of IBD or the control group (Strauss et al., 2011). *Fusobacterium* species have also been linked to colorectal carcinoma (Mima et al., 2015) and interestingly, IBD is a recognized risk factor for colorectal carcinoma (Lutgens et al., 2015). The reduction of particular commensal microbes and a concomitant loss of their protective function possibly have a substantial impact on the course of disease. The ability of commensal bacteria to produce SCFA including butyrate, acetate and propionate via dietary fiber (a prebiotic) fermentation is a key benefit to the human gut. SCFA are a primary source of energy for colonic epithelial cells and have recently been shown to mediate homeostasis of colonic regulatory T cell populations (Smith et al., 2013). The abundance of *Faealbacterium* of the Ruminococcaceae family is reduced in IBD (Lopez-Siles et al., 2015). *F. prausnitzii* is an anti-inflammatory commensal bacterium and produces the SCFA butyrate. *F. prausnitzii* administration in mouse models has been shown to reduce

**TABLE 1 | Continued**

| IMID     | Subjects                                      | Comments                                      | Reference                |
|----------|-----------------------------------------------|-----------------------------------------------|--------------------------|
| SLE      | Twenty SLE patients in remission              | Decreased Firmicutes/Bacteroidetes ratio. Reduction of Lachnospiraceae and Ruminococcaceae, enrichment of Bacteroidales. | Hevia et al., 2014       |
| PsA      | Fifteen patients with psoriasis of the skin; 16 PsA | Reduced diversity. Coprococcus decreased in psoriasis and PsA. Akkermansia, Ruminococcus, Pseudobutyribio decreased in PsA. | Scher et al., 2015       |
| PsA      | Twenty-nine psoriasis; 31 IBD; 13 concomitant psoriasis and IBD | Lower abundance of *F. prausnitzii* and higher abundance of *E. coli* | Eppinga et al., 2015     |
inflammation and secondly, a reduction in the abundance of F. prausnitzii has been linked to postoperative disease recurrence in ileal CD (Sokol et al., 2008). The abundance of other SCFA producers including the Leuconostocaceae, Odoribacter splanchnii, Phascolarctobacterium, and Roseburia are reduced in IBD (Morgan et al., 2012; Machiels et al., 2014). Roseburia hominis, in particular, inversely correlates to UC disease activity and duration (Machiels et al., 2014) and has been described as an acetate user and butyrate producer and is therefore dependent on other SCFA producers (Duncan et al., 2002). Alterations of these bacterial populations and concurrent variability of SCFA production may have profound consequences on host regulatory mechanisms of inflammation, though studies haven’t established causality.

Multiple Sclerosis (MS)

Multiple sclerosis is a chronic inflammatory demyelinating disorder of the CNS. The cause of disease is not entirely understood, but both genetic and environmental components are involved in disease susceptibility (Dendrou et al., 2015). Though the CNS was originally regarded as an immune-privileged compartment, it is now recognized that immune cells survey the CNS regularly (Zhang et al., 1994); in MS and related neurological diseases there is an enrichment of autoreactive immune cells targeting elements of the CNS (myelin in MS). The discovery that gut microbes can produce neurotransmitters that can in turn influence the enteric nervous system and ultimately the CNS has led to the notion of the microbiota-gut-brain axis (Wang and Kasper, 2014).

Research investigating the role of the gut microbiome in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, suggests a relationship between the gut microbes and development of MS. Ochoa-Repáraz et al. (2009) utilized a cocktail of oral antibiotics (ampicillin, vancomycin, neomycin sulfate, and metronidazole) to disrupt the gut microbiome of mice prior to induction of EAE. The authors reported oral antibiotic treatment significantly decreased gut bacterial populations and reduced the onset and severity of EAE. The reduced severity of EAE was ascribed to decreased levels of pro-inflammatory cytokines and chemokines and elevated levels of anti-inflammatory cytokines including IL-10 and IL-13; IL-17A, both of which play critical roles in the development of EAE. Increased Foxp3+ Treg cells in the peripheral lymphoid tissues and the CNS were observed in germ-free mice. The authors further reported that SFB monocolonization of mice restored disease and examination of CNS tissues showed enhanced invasion by Th1 and Th17 cell populations. Using a relapsing-remitting mouse model (SJL/J) of spontaneously developing EAE, Berer et al. (2011) reported that the commensal gut microbiota is essential in triggering immunological processes that lead to relapsing-remitting autoimmune disease and that myelin-specific CD4+ T cells were driving factors of autoimmunity. Additionally, the activation of autoantibody-producing B cells was shown to be dependent upon the availability of the myelin autoantigen (specifically, MOG) and the gut microbiota.

The ability of probiotics to modify the clinical outcome of murine EAE has also been investigated. Prophylactic treatment with Lactobacillus paracasei and L. plantarum DSM 15312 was shown to induce Treg cells in mesenteric lymph nodes and enhance production of TGFβ1 whereas increased serum IL-27 levels were observed with L. plantarum DSM 15313 (Lavasani et al., 2010). Interestingly, administration of each strain independently was unsuccessful therapeutically whereas combinatorial administration suppressed disease perpetuation and reversed clinical signs of EAE. Disease amelioration was attributed to attenuation of the pro-inflammatory Th1/Th17 response and induction of Treg cells through elevated IL-10 levels. Comparably, an additional probiotic, Bifidobacterium animalis demonstrated similar suppressive effects (Ezendam et al., 2008). It has also been reported that some probiotic bacteria, notably L. casei Shirota, enhanced the duration of EAE (Ezendam and van Loveren, 2008); however, this was refuted in a subsequent study that determined neither L. casei Shirota nor B. brevis strain Yakult exacerbates EAE (Kobayashi et al., 2010). Prophylactic administration of five probiotics (IRT5; L. casei, L. acidophilus, L. reuteni, B. bifidum, and Streptococcus thermophilus) prior to disease induction significantly suppressed development of EAE (Kwon et al., 2013) whereas treatment with IRT5 to EAE delayed disease onset. Prophylactic and therapeutic efficacy of IRT5 probiotics was ascribed to inhibition of Th1 and Th17 responses and induction of IL-10-producing and/or Foxp3+ Treg cells.

To further explore how the microbiome affects EAE susceptibility and severity, the role of particular commensals or their products was considered. Ochoa-Repáraz et al. (2010b) investigated oral treatment of mice with polysaccharide A (PSA) of B. fragilis. In PSA treated mice, EAE severity was decreased relative to untreated mice and decreased numbers of Th1 and Th17 cells were reported in the EAE brains of PSA-treated mice. Moreover, lymphocytes isolated from the cervical lymph nodes of PSA-treated mice reportedly produced more IL-10 and less IL-17 and IFN-γ when stimulated with myelin oligodendrocyte glycoprotein (induction of EAE). Phosphorylated dihydroceramides, lipids derived from the oral commensal P. gingivalis, demonstrated enhanced EAE severity.
through induction of DC IL-6 secretion in a TLR2-dependent manner and a subsequent decrease in Foxp3\textsuperscript{T} Treg cell populations (Nichols et al., 2009). A recent study demonstrated oral administration of a \textit{Lactococcus lactis} strain that produces heat shock protein-65 prevented development of murine EAE; the suppressive effect was ascribed to elevated IL-10 and reduced IL-17 production (Rezende et al., 2013).

Little is known about what impact the gut microbiome may have on human MS etiopathogenesis; gut microbiome studies are mostly limited to case-control examinations in persons with MS. Mowry et al. (2012) reported relapsing-remitting MS (RRMS) patients to have differing levels of Firmicutes, Bacteroidetes, and Proteobacteria, and that shifts in the abundance of Firmicutes was more dramatic in patients treated with glatiramer acetate, an immunomodulator drug. Comparatively, vitamin D treatment was associated with changes in Firmicutes, Actinobacteria, and Proteobacteria in RRMS patients, and increases in Enterobacteria in both RRMS and healthy controls. Vitamin D has been a main suspect in MS etiology for some time (Holmøy and Torkildsen, 2016). The beneficial aspects of vitamin D in the treatment of MS including exerting anti-inflammatory effects, possible influence on remyelination and its link to disease activity is widely accepted and is actively used as a therapeutic (Jarrett et al., 2014). The mechanism of benefit is unknown but it is plausible that it has an impact on the gut microbiome. Additional analysis by the same group revealed that although overlap of bacterial communities has been observed. Particular taxa including \textit{Faecalibacterium} were reported to be lower in persons with MS (Cantarel et al., 2015). Of note, \textit{Faecalibacterium} is considered to be immunosuppressive through production of the SCFA butyrate. Glatiramer acetate-treated patients showed differences in microbe composition including Bacteroidaceae, \textit{Faecalibacterium}, \textit{Ruminococcus}, \textit{Lactobacillaceae}, \textit{Clostridium}, and additional Clostridiales compared to untreated persons. After vitamin D supplementation, untreated persons with MS had an increase in \textit{Akkermansia}, \textit{Faecalibacterium}, and \textit{Coprococcus}. Although these studies are exploratory and future studies in larger cohorts are needed to confirm these findings, these results suggest that the microbial communities of the MS gut are subject to modulation by some drugs commonly used in the treatment of MS. Jhangi et al. (2014) found a significant increase in the highly immunogenic Archaea \textit{Methanobrevibacter smithii}, which might play a role in inflammation due to their structural components. Butyricimonas and Lachnospiraceae, which are butyrate producers with anti-inflammatory properties, were lower in untreated MS. Tremlett et al. (2015) explored gut microbiome profiles in pediatric MS; increases in \textit{Escherichia}, \textit{Shigella}, and \textit{Clostridium} were observed, and decreases in \textit{Eubacterium rectale} and \textit{Corynebacterium}. Recently, the association between gut community profiles in 15 pediatric RRMS patients and host immunological markers such as IFN-\textgamma, IL-17, IL-10, CD4\textsuperscript{+}CD25\textsuperscript{+}Foxp3\textsuperscript{T} Treg were explored (Tremlett et al., 2016a). The authors reported immune markers did not differ between RRMS and controls but did observe divergence in the association between the gut microbiome and immunological markers. IL-17\textsuperscript{T} cells positively correlated with overall richness and evenness whereas an inverse correlation between IL-17\textsuperscript{T} T cells and Bacteroidetes abundance in MS was reported. Another study reporting on the association between the gut microbiota composition and relapse risk in pediatric MS showed a decrease in Fusobacteria, increase in Firmicutes and the presence of the Archaea Euryarchaeota was associated with a shorter time to relapse (Tremlett et al., 2016b). Thus far, current studies indicate that gut dysbiosis is linked with MS. Common findings include a reduction in the phyla Bacteroidetes and Firmicutes, which are important for immunoregulation and production of SCFA.

**Rheumatoid Arthritis (RA)**

Rheumatoid arthritis is a common systemic autoimmune disease that manifests in the joints and if untreated can lead to chronic joint deformity, disability and increased mortality owing to cardiovascular and other concurrent, systemic complications. Notwithstanding recent advances in understanding the pathogenesis of RA (McInnes and Schett, 2011), the etiology remains undefined. Numerous genetic susceptibility risk alleles have been identified, but are insufficient to account for disease incidence. Therefore, RA is considered a multifactorial disease requiring both genetic and environmental factors for disease onset and/or progression.

Gut bacteria as an autoimmune trigger in RA has been recognized for decades. Mannson and Coll Dahl (1965) reported the majority of RA patients to have an intestinal flora with increased amounts of \textit{Clostridium perfringens} type A in their feces. The patients also showed immune responses with elevated antibody titers to \textit{C. perfringens} alphatoxin and positive skin tests. Ultimately, the elevation of \textit{C. perfringens} was not specific to RA but was instead identified in a number of diseases, in particular, other chronic arthritides. It was later hypothesized that there are many bacteria involved in the pathogenesis of RA and not just one bacterium (Gullberg, 1978).

An accumulating body of literature exists to support a connection between gut bacteria and arthritis or more commonly referred to as the ‘gut–joint axis’ hypothesis. The groundbreaking study to identify the pro-arthritogenic role played by intestinal bacteria was reported by Kohashi et al. (1979) who discovered germ-free rats developed severe joint inflammation with 100% incidence in an adjuvant-induced arthritis model as compared to conventionally raised controls that developed less severe arthritis and at a modest incidence. This observation suggests that the gut microbiota may have important immunosuppressive effects. Other notable early findings supporting gut involvement in RA include studies reporting either protective or proarthritogenic roles of \textit{E. coli} and \textit{Bacteroides} species when introduced into germ-free arthritis-prone rats (Kohashi et al., 1985, 1986; Rath et al., 1996); germ-free \textit{HLA-B27} transgenic rats remained unaffected from inflammatory (intestinal and peripheral) joint disease (Taurog et al., 1994), and germ-free rats become susceptible to arthritis –attributed to a loss of T-cell tolerance– in a streptococcal cell wall-induced rat arthritis model (van den Broek et al., 1992). More recently, Abdollahi-Roodsaz et al. (2008) determined arthritis is attenuated in IL-1 receptor antagonist-knockout (\textit{Il1rn}{\textsuperscript{−/−}}) mice (a model whereby mice
spontaneously develop an autoimmune T-cell mediated arthritis. Applying gnotobiological methods, the introduction of the commensal species *Lactobacillus bifidus* resulted in disease onset. Development of arthritis in this model was attributed to an imbalance of Treg-Th17 homeostasis. Additional evidence comes from a study using the K/BxN T-cell receptor transgenic model of inflammatory arthritis (Wu et al., 2010). Germ-free mice did not develop disease, implying the gut microbiota is critical to the development of arthritis; protection of arthritis was ascribed to an absence of peripheral Th17 cells. Interestingly, monoclonization of germ-free K/BxN mice with SFB effectively stimulated an autoimmune response thereby resulting in arthritis; autoimmunity developed as a result of promoting Th17 cells. Collectively, the above data derived from germ-free and gnotobiotic experimental animal models imply that the gut microbiota – particularly in a state of dysbiosis – is deemed necessary to trigger autoimmunity and consequent inflammatory arthritis. Moreover, the transition from a ‘normal’ gut microbiota to a state of dysbiosis likely requires a genetic predisposition.

One of the initial microbiome surveys in RA reported that persons early in disease course (disease duration ≤ 6 months) harbor significantly less bifidobacteria, *Bacteroides fragilis* subgroup, bacteria of the *Eubacterium rectale* – *Clostridium cocoides* subgroup and *Bacteroides–Porphyromonas–Prevotella* groups in comparison to persons with non-inflammatory fibromyalgia (Vaathovuo et al., 2008). Another study specifically examined the relationship of *Lactobacillus* to RA (Liu et al., 2013); the authors identified significantly more *Lactobacillus* (10.62 ± 1.72 copies/g) in the RA gut compared to healthy controls (8.93 ± 1.60 copies/g). Furthermore, an increase in diversity and bacterial abundance was reported suggesting a possible relationship between *Lactobacillus* populations and disease onset and/or progression of RA. The abundance of *Lactobacillus* communities in RA, and other IMID, is relevant as these microorganisms and others are considered probiotic microbes that may confer a health benefit to the host. Sher et al. (2013) identified a strong association between *Prevotella copri* with new-onset untreated RA (NORA) and increases in the abundance of *Prevotella* corresponded with a reduction of several beneficial microbes, including the *Bacteroides*. Moreover, a negative correlation between the relative abundance of *P. copri* and the presence of shared epitope risk alleles was identified, indicating that the role of *P. copri* may play a more important role in persons with a lower load of genetic susceptibility. Zhang et al. (2015) recently analyzed the fecal, dental and salivary microbiome from treatment-naïve RA and unrelated healthy controls, as well as treatment-naive RA paired with healthy relatives and DMARD-treated RA patients, representing the largest RA cohort and most comprehensive metagenomics analysis to date. The fecal analysis showed that *Haemophilus* were depleted and *Lactobacillus salivarius* was over-represented in RA, and that more dramatic changes in abundance were observed in cases of active disease. In contrast, the abundance of *P. copri* was detected as a function of RA duration within the first year. Metagenomic linkage groups comprised of *Clostridium asparagiforme*, *Gordonibacter pamelaeae*, *Eggerthella lenta*, and *Lachnospiraceae bacterium* as well as *B. dentium*, *Lactobacillus* sp., and *Ruminococcus lactaris* were enriched in the RA gut. The investigators also showed that the altered gut microbiome could be used to identify RA patients, correlated with clinical indices [for example, titers of immunoglobulin A (IgA), major serum immunoglobulin (IgG), platelet count, anticyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF)], and could be utilized to stratify individuals based on their therapeutic response with disease-modifying anti-rheumatic drugs (DMARDs). And functionally, the redox environment and transport and metabolism of iron, zinc and sulfur were altered in persons with RA. A newly published study examined the microbial and metabolite profile in RA (Chen et al., 2016). RA patients were found to demonstrate a reduced microbial diversity and this correlated to disease duration and antibody levels. The gut in persons with RA was characterized by an expansion of the typically low-abundant phylum Actinobacteria and a decrease in more dominant phyla. The genera *Eggerthella* and *Actinomyces* of the Actinobacteria and *Turbicibacter* and *Streptococcus* of the Firmicutes were significantly expanded in RA whereas the abundance of *Faecalibacterium* was significantly reduced. Moreover, the abundance of *Collinsella* correlated with high levels of alpha-aminoadipic acid and asparagine and IL-17A production. The study also confirmed the role of *Collinsella* in altering gut permeability and disease severity in experimental arthritides.

### Ankylosing Spondylitis (AS)

Ankylosing spondylitis belongs to a group of arthritides referred to as spondyloarthropathies. AS primarily targets the spine and sacroiliac joints and is characterized by enthesal inflammation. Disease progression is characterized by excessive bone formation (ankylosis) and eventually fuses joints, resulting in pain, stiffness, morbidity, and increased mortality (Thomas and Brown, 2010). The etiology of AS is unclear although environmental and genetic associations are considered to play a role. AS has been linked with the HLA-B27 allele since the 1970s (Schlosstein et al., 1973) and the recurrence risk among siblings and first degree relatives is 8.2% versus the general population with a risk of 0.1% (Brown et al., 2000).

Gut involvement in AS has been recognized for decades. Clinically, between 5 and 10% of persons with AS develop IBD at some time, and 70% of persons with AS are diagnosed with subclinical gut inflammation (Mielants et al., 1991). Relatively few studies have characterized the gut microbiome as it relates to AS. An early study by Stebbings et al. (2002) utilizing denaturing gradient gel electrophoresis reported no discernable differences in microbe populations of stool between 15 AS patients and 15 matched healthy controls as all subjects had unique and stable community profiles. Further analysis revealed a higher proportion of AS fecal samples contained sulfate-reducing bacteria [similar to IBD (Kushkevych, 2014)] compared to controls and a potential loss of immunological tolerance to autologous *Bacteroides*. Newly published evidence reveals a distinct microbial signature in the terminal ileum: Costello et al. (2015) recently surveyed the AS gut microbiome via 16S rRNA sequencing using terminal ileal biopsies from...
Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus is a multi-system IMID with many clinical phenotypes and commonly involves the skin, joints, brain, kidneys, serosal surfaces, blood cells, blood vessels, heart, and lungs (Goldblatt and O’Neill, 2013). SLE affects persons with a wide spectrum of symptoms and disease courses including most frequently constitutional symptoms, malar (butterfly) rash, arthritis or arthralgia, renal and hematological symptoms (Goldblatt and O’Neill, 2013). From an immunological point of view, SLE demonstrates aberrant responses at varying levels: uncontrolled T-cell differentiation and activation, abnormal polyclonal B-cell activation and proliferation and autoantibody production linked to immune complex formation (Mok and Lau, 2003). It is the B-cell hyperactivity resulting in the production of several autoantibodies including those against double-stranded DNA, nucleosomes, phospholipids, N-methyl-D-aspartate receptor, C1q, and others (Goldblatt and O’Neill, 2013) that is a key pathological feature of SLE.

The role of the gut microbiome in SLE is an emerging field of research. Hevia et al. (2014) recently reported the first comprehensive characterization of the SLE gut microbiome: significant decrease in the Firmicutes/Bacteroidetes ratio was observed, similar to shifts observed in type 2 diabetes (Larsen et al., 2010) and CD (Manichanh et al., 2006). The change of Firmicutes/Bacteroidetes abundance in SLE was attributed to members of the orders Bacteroidales (Bacteroidetes) and Clostridiales (Firmicutes). Lachnospiraceae and Ruminococcaceae were positively associated with healthy controls. Some species of the Lachnospiraceae family like Roseburia sp. and Butyribrio sp. are butyrate producers; butyrate production in the human gut is highly relevant as it promotes Treg cell differentiation which can ultimately suppress pro-inflammatory responses (Singh et al., 2014). Bacteroides were significantly higher in SLE patients and Desulfovibrio were significantly reduced. The study also explored the functionality of the microbiome: glycan degradation pathways, lipopolysaccharide biosynthesis proteins and oxidative phosphorylation processes were associated with SLE partly explained by the increased abundance of Bacteroidetes, and more specifically Bacteroides. Another study by the same group performed a metabolome-wide scan of the gut microbiome (Rojo et al., 2015). The authors observed a slight difference (0.72% of metabolic mass features) in the gut metabolome but not in taxa composition and abundance of the gut microbiota. Cuervo et al. (2015) investigated the influence of dietary components to the gut microbiome of SLE. Positive correlations were identified between flavone and Blautia, flavonanes, and Lactobacillus, and dihydrochalcones and Bifidobacterium in SLE; dihydroflavanols directly associated with Faecalibacterium and flavanol inversely correlated with Bifidobacterium in healthy controls.

Several studies utilizing murine models have demonstrated that gut dysbiosis might in fact be causal in the development of SLE. The effect of host genetics, sex, age, and dietary factors was recently investigated in a murine lupus model (Zhang...
The female to male ratio for SLE is 10:1 and incidence rates at age 20–29 is highest (Jarukitsopa et al., 2015). Overall, young, female lupus-prone mice showed an increase in Lachnospiraceae and Bacteroidetes and a decrease in Bifidobacteriaceae and Erysipelotrichaceae. Diversity was also increased and lactobacilli were present in reduced numbers. The functional profile of lupus-prone mice revealed bacterial motility and sporulation-related pathways to be enriched. Retinoic acid as a dietary factor was found to restore lactobacilli populations, which correlated with reversing SLE functional pathways and improved symptoms. Additionally, the gut microbiome of lupus-prone mice differed between sexes; Lachnospiraceae were overrepresented in females that were found to correlate to earlier disease onset and/or increased diseases severity. A recent study assessing the impact of dietary factors on the development of SLE prone mice revealed significant differences in gut microbiome composition during pre-nephritic stages in mice drinking neutral (pH 7.0–7.2) versus acidic water (pH 3.0–3.2) and that mice drinking acidic water demonstrated lower levels of SLE-associated antibodies (anti-dsDNA and anti-nucleohistone), lower immune cell infiltrates in the kidney, and a slower progression of nephritis (Johnson et al., 2015).

Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic, inflammatory multi-organ disease, with a well-characterized and even pathognomonic pathology primarily manifesting in the skin and frequently the joints. The pathophysiology is dynamic and multifaceted, involving a complex interplay between genetics [HLA-Cw06 allele variant confers strongest susceptibility (Nair et al., 2006)], environmental triggers and both the innate and adaptive immune systems. Furthermore, approximately 24% of persons with psoriasis have concurrent psoriatic arthritis (Prey et al., 2010), a complex disorder involving peripheral and axial joints, dactylitis, enthesitis, and psoriasis.

Particular phenotypes of psoriasis have long been clinically linked to tonsillar infection with group A β-haemolytic streptococci (Valdimarsson et al., 1995), and exacerbation of disease with skin or gut colonization by Staphylococcus aureus and fungi Candida albicans and Malassezia (Fry and Baker, 2007), however, studies investigating the correlation of psoriasis with the microbiome of the skin or gut are in their infancy. Fahlén et al. (2012) surveyed the cutaneous psoriasis microbiome via 16S rRNA sequencing. The study demonstrated that the Proteobacteria phylum was overrepresented and the abundance of Staphylococci and Propionibacteria was lower in psoriasis versus control skin. A recent study characterizing the gut microbiome reported an overall reduction of bacterial diversity and depletion of multiple (beneficial) gut bacteria in psoriasis and psoriatic arthritis and that changes in abundance were more dramatic in psoriatic arthritis (Scher et al., 2015).

Both patient groups showed a decrease in Coprococcus species whereas psoriatic arthritis showed a reduction of Akkermansia, Ruminococcus, and Pseudobutyryrivibrio. Interestingly, the authors determined that the gut microbiota profile of psoriatic arthritis is similar to the profile commonly observed in the IBD gut. Another study identified an IBD-like decrease of Faecalibacterium prausnitzii and increase of E. coli adding further support of a gut-skin axis (Eppinga et al., 2015). Gut dysbiosis in psoriatic arthritis has been shown to correlate to an increase of secretory IgA (sIgA) levels and a decrease of receptor activator of nuclear factor kappa-B ligand (RANK-L) levels within the gut luminal content (Scher et al., 2015). These results suggest that sIgA and/or RANK-L may be signs of a gut barrier breach due to dysbiosis or their possible role of disseminating inflammation to distant organs.

The Gut Virome in Immune-Mediated Inflammatory Disease
To date, human microbiome studies have largely focused on bacterial components of the microbiome, though emerging data suggest that the viral components of the microbiome (virome) can have a profound impact on the host. Advances in sequencing technology and bioinformatics analysis have led to the discovery of a diverse human gut virome comprised of eukaryotic viruses and bacteriophages (viruses that infect bacteria) that outnumber human cells by 100-fold (Mokili et al., 2012). The functionality of the virome is not well defined although recent studies suggest the virome does in fact play an important role. It has been shown that a common enteric RNA virus, murine norovirus, can replace the beneficial function of commensal bacteria in germ-free or antibiotic-treated mice (Kernbauer et al., 2014). Importantly, eukaryotic viruses have demonstrated an interaction with IBD susceptibility genes to alter gut microbial populations as demonstrated in studies of mice carrying mutations in Il-10 (Basic et al., 2014) or Atg16l1 (Cadwell et al., 2010).

In the absence of disease, gut bacteriophage populations exhibit significant diversity and are predominated by members of the Caulovirales or Microviridae (Castro-Mejía et al., 2015). A number of studies have investigated the role of bacteriophages with respect to IBD. The abundance of bacteriophages in mucosal biopsies are significantly increased in CD versus healthy controls (Lepage et al., 2008), and are also more diverse in pediatric CD compared to healthy controls (Wagner et al., 2013). New evidence demonstrates that disease-specific alterations exist in the gut virome in IBD (Norman et al., 2015). This study showed that the IBD gut virome is abnormal; the gut virome richness is increased and a significant expansion of Caulovirales was observed in both CD and UC, but particular viromes of CD and UC were disease and cohort specific. Importantly, the expansion and diversification of the gut virome was found to be independent from alterations in bacterial populations.

As virome profiling in health and disease is a relatively new field, data are currently limited to investigations of IBD. With numerous viral infections as potential environmental triggers in IMID, particularly Epstein-Barr virus or cytomegalovirus in MS (Belbasis et al., 2015) and several other lines of evidence that indicates a role for viruses, we anticipate future studies will target the gut virome in other IMID.
The Gut Mycobiome in Immune-Mediated Inflammatory Disease

The human fungal microbial populations (mycobiome) are now appreciated as complex and important for human health. Research of the mycobiome has only recently begun, particularly in health and in IBD. Fungal DNA accounts for approximately 0.2% of the mucosa-associated microbiota and 0.3% of the fecal microbiota (Ott et al., 2008). The fungal constituents of the healthy human gut have been characterized and were found to contain Aspergillus, Candida, Cryptococcus, Penicillium, Pneumocystis, and Saccharomyces (Dollive et al., 2012). In IBD, the fecal mycobiome was recently reported to be skewed (Sokol et al., 2016). Specifically, the authors observed an increased Basidiomycota/Ascomycota ratio, a reduced abundance of *Saccharomyces cerevisiae* and an increased abundance of *Candida albicans* relative to healthy controls. The study also explored the relationship between fungal and bacterial populations and suggests that CD may favor fungi at the expense of bacteria and that disease-specific inter-kingdom alterations exist. Mukhopadhy et al. (2014) studied the mycobiome in newly diagnosed pediatric IBD patients and found the phylum Basidiomycota to dominate in IBD whereas Ascomycota dominated in healthy controls. A higher fungal diversity has also been reported in CD but no disease-specific fungal species were reported in either CD or UC (Ott et al., 2008). Fungal abundance has also been linked to diet (Hoffmann et al., 2013; *Candida* positively associated with carbohydrate consumption and negatively associated with saturated fatty acid levels whereas *Aspergillus* negatively associated with SCFA levels in a carbohydrate-rich diet. Interestingly, anti-*Saccharomyces cerevisiae* antibodies (ASCA) have a role in diagnosis, disease phenotype and prognosis in CD (Russell et al., 2009).

Other domains of microorganisms including the archaea, fungi, or viruses are increasingly being recognized to have important functions in host health. However, in terms of studying the microbiota, research has been very bacteria-centric, as only a limited number of studies have investigated the micro-eukaryotes or viral components in IMID.

Therapeutic Manipulation of the Gut Microbiome

The gut microbiota is increasingly being recognized as an attractive target for therapeutic intervention. Exposure to particular antibiotics is a known risk factor for development of some IMID, however, antibiotics may also impact on IMID disease course by reducing concentrations of luminal gut bacteria and subsequently alter the gut microbiota composition in a way that is beneficial to the host, resulting in the induction of remission and/or the prevention of relapse. For example, even in the absence of robust clinical evidence antibiotics have been considered by some as an effective therapy in IBD and routinely used as a therapeutic strategy. A diverse group of antibiotics including macrolides, fluoroquinolones, 5-nitroimidazoles, rifaximin, and antimycobacterial therapy either administered alone or in combination have been evaluated in clinical trials for IBD treatment. In a meta-analysis antibiotics were found to be superior to placebo (Khan et al., 2011). However, the antibiotics had such a disparate spectrum of activity the results of this meta analysis raises the question as to whether it is important to attack a specific spectrum of organisms or simply important to alter the gut microbiome in any way. Antibiotic treatment for RA has been utilized without a firm rationale as early as the 1930s with sulfasalazine, a combination of sulphapyridine and 5-aminosalicylic acid (Svartz, 1948), and later with tetracycline derivatives (Brown et al., 1971). A number of clinical trials have evaluated the use of minocycline (Kloppenburg et al., 1994; Tilley et al., 1995; O’Dell et al., 1997, 2001), macrolides (Saviola et al., 2002, 2013; Ogrendik, 2007a, 2009; Ogrendik and Karagoz, 2011) and levofloxacin (Ogrendik, 2007b) for the treatment of RA. Evidence concerning therapeutic use of antibiotics in MS is limited; use of minocycline for clinically isolated syndrome and RRMS is currently in phase III of clinical trials (Metz et al., 2009). There is currently no indication that antibiotics are beneficial in SLE or most spondyloarthropathies.

Repopulating the gut with a healthy community is an alternative approach to perturbing the existing microbiome, but so far, outcomes from these methods are controversial or not efficacious. Probiotics are dietary supplements that contain live microorganisms that when administered are thought to strengthen the existing gut microbiome. For IBD, the efficacy of probiotics in clinical outcomes demonstrates variable success. A recent meta-analysis of randomized controlled trials evaluating the effectiveness of probiotics reported probiotic supplementation is linked to inducing remission/response in active UC but not CD (Shen et al., 2014). And, only VSL#3 (a combination of *L. casei*, *L. plantarum*, *L. acidophilus*, *L. delbruekii* subsp. *bulgaricus*, *B. longim*, *B. breve*, *B. infantis*, and *S. salivarius* subsp. *thermophilus*) significantly increased remission/response rates. Studies indicate that probiotics cannot treat CD and UC with equal effectiveness suggesting altering a single parameter might not be enough to cure disease. There is clinical evidence that probiotics (*L. casei* 01) as adjunctive therapy improves disease activity and inflammatory status in patients with RA (Vaghef-Mehrabany et al., 2014). In contrast, a probiotic preparation containing *S. salivarius*, *B. lactis*, and *L. acidophilus* demonstrated no significant benefit in patients with spondyloarthritides (Jenks et al., 2010). There are currently no published clinical trials to date of probiotic administration in MS or SLE, though studies utilizing mice suggest a potential benefit in both SLE (Alard et al., 2009) and MS (discussed above).

Prebiotic refers to a food substance that may be fermented but not digested. The fermentation of prebiotics stimulates growth and activity of gut microbes potentially benefiting the host via production of energy and metabolic substrates. Studies evaluating the clinical use of prebiotics in specific diseases are limited, with the exception of CD. The administration of 15 g of fructo-oligosaccharides (inulin) in patients with active ileocolonic CD has shown both promising results (Lindsay et al., 2006) and no clinical benefit (Benjamin et al., 2011). A 10 g lactulose administered to active CD patients demonstrated no significant improvement (Hafer et al., 2007). Prebiotics may be bloating and may in themselves lead to gastrointestinal symptoms.
Fecal microbiota transplantation (FMT) is another approach that can be used in diseases linked to gut dysbiosis. FMT is a novel technique in which the gut microbiota are transferred from a healthy donor to the patient with the overall goal to introduce a stable microbial community in the gut. Until recently, FMT has primarily been utilized to successfully treat recurrent antibiotic-resistant *C. difficile* infection (van Nood et al., 2013). The clinical efficacy of FMT in UC is promising as FMT has been shown to induce remission in a greater percentage of patients than placebo and no difference in adverse events were reported (Moayyedi et al., 2015). FMT has been investigated in fewer other diseases including CD (Gordon and Harbord, 2014; Quera et al., 2014) as case reports, albeit data are too limited to determine clinical usefulness. More randomized controlled trials are warranted to evaluate donor selection and the frequency of FMT administration.

CONCLUSION AND PERSPECTIVES

Immune-mediated inflammatory diseases are multifaceted disorders that share many common underlying dynamics including epidemiological co-occurrence, genetic susceptibility, and numerous environmental factors. IMID are highly influenced by the structural and functional characteristics of the gut microbiome. Recent technological advancements have facilitated comprehensive analyses through large cohort studies and have expanded our knowledge of the structure and function of the gut in health and in many diseases. Most available gut microbiome research is correlative and experimental models for testing hypotheses emergent from correlative associations are necessary. Investigation of the microbiome and relevant mechanisms poses a significant challenge because of the complexity of the relationships between the microbiota with host genetics and environmental factors. Nevertheless, many microbiome surveys have focused on only a single IMID; future microbiome studies should include multiple disease cohorts to characterize the gut microbial populations simultaneously to accurately examine how particular microbial groups are altered between IMID.

AUTHOR CONTRIBUTIONS

JF participated in developing the idea for the article, drafting the article, and participated in the final editing. GV participated in developing the idea for the article and participated in the final editing. CB participated in developing the idea for the article and participated in the final editing.

FUNDING

JF is funded in part by the Mindel and Tom Olenick Studentship. CB is funded in part by the Bingham Chair in Gastroenterology.

ACKNOWLEDGMENT

The authors thank Andrea Tyler for her expert review of the manuscript.

REFERENCES

Abbott, A. (2016). Scientists bust myth that our bodies have more bacteria than human cells. *Nature* doi: 10.1038/nature2016.19136

Abdollahi-Roodsaz, S., Joosten, L. A. B., Koenders, M. I., Devesa, I., Roelofs, M. F., Radstake, T. R., et al. (2008). Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. *J. Clin. Invest.* 118, 205–216. doi: 10.1172/JCI32639

Adams, L. A., and Morrison, M. (2016). The microbiome in obesity, diabetes, and NAFLD: what is your gut telling us? *Curr. Hepatol. Rep.* 15, 96–102. doi: 10.1007/s11901-016-0299-5

Agus, A., Denizot, J., Thévenot, J., Martinez-Medina, M., Massier, S., Sauvanet, P., et al. (2016). Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive *E. coli* infection and intestinal inflammation. *Sci. Rep.* 6:19032. doi: 10.1038/srep19032

Alard, P., Parnell, S., Manirarora, J., Kosiewicz, M., and Atay, S. (2009). Probiotics control lupus progression via induction of regulatory cells and IL-10 production. *J. Immunol.* 182:30.

Anantakrishnan, A. N. (2015). Environmental risk factors for inflammatory bowel diseases: a review. *Dig. Dis. Sci.* 60, 290–298. doi: 10.1007/s10620-014-3350-9

Arpalia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 504, 451–455. doi: 10.1038/nature12726

Asquith, M., Stauffer, P., Davin, S., Mitchell, C., Lin, P., and Rosenbaum, J. T. (2016). Perturbed mucosal immunity and dysbiosis accompany clinical disease in a rat model of spondyloarthritis. *Arthritis Rheumatol.* doi: 10.1002/art.39681 [Epub ahead of print].

Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., et al. (2013). Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature* 500, 232–236. doi: 10.1038/nature12331

Backhed, F., Roswall, J., Peng, Y., Feng, Q., Iia, H., Kovatcheva-Datchary, P., et al. (2015). Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe* 17, 690–703. doi: 10.1016/j.chom.2015.04.004

Basic, M., Keubler, L. M., Buettner, M., Achar, M., Breves, G., Schröder, B., et al. (2014). Norovirus triggered microbiota-driven mucosal inflammation in interleukin 10-deficient mice. *Inflamm. Bowel Dis.* 20, 431–443. doi: 10.1097/IBD.0000441346.86827.ed

Barry, J., and Radstake, T. R. (2013). Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies. *Expert Rev. Clin. Immunol.* 9, 297–299. doi: 10.1586/erci.13.10

Becker, C., Neurath, M. F., and Wirtz, S. (2015). The intestinal microbiota in inflammatory bowel disease. *ILAR J.* 56, 192–204. doi: 10.1093/ilar/ivt030

Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A., and Tsoulaki, I. (2015). Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol.* 14, 263–273. doi: 10.1016/S1474-4422(14)70267-4

Benjamin, J., Hedin, C., Koutsoumpa, A., Ng, S., McCarthy, N., Hart, A., et al. (2011). Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. *Gut* 60, 923–929. doi: 10.1136/gut.2010.232025

Berer, K., Mues, M., Koutolos, M., Rasbi, Z. A., Bozikic, M., Johner, C., et al. (2011). Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination - with comments. *Nature* 479, 538–541. doi: 10.1038/nature10554

Bernstein, C. N., Blanchard, J., Houston, D., and Wajda, A. (2001a). The incidence of venous thromboembolic disease among patients with IBD: a population-based study. *Thromb. Haemost.* 85, 430–434.
Claesson, M. J., Jeffery, I. B., Conde, S., Power, S. E., O'Connor, E. M., Cusack, S., Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A. L., Barnich, N., Chen, J., Wright, K., Davis, J. M., Jeraldo, P., Marietta, E. V., Murray, J., et al. (2016). Metagenomics reveals dysbiosis and a potentially pathogenic \textit{N. flavescens} strain in duodenum of adult celiac patients. \textit{Am. J. Gastroenterol}. 111, 879–890. doi:10.1038/ajg.2016.95

Daulatrai, M. A. (2014). Obesity and gut's dysbiosis promote neuroinflammation, cognitive impairment, and vulnerability to Alzheimer’s disease: new directions and therapeutic implications. \textit{Mol. Genet. Med.} 5:1005. doi:10.1111/mgm.12073

David, L. A., Materna, A. C., Friedman, J., Campos-Baptista, M. I., Blackburn, M. C., Perrotta, A., et al. (2014). Host lifestyle affects human microbiota on daily timescales. \textit{Genome Biol.} 15:R89. doi:10.1186/gb-2014-15-7-r89

de Mejia, T., de Groot, E., Benninga, M., Budding, D., de Boer, N., van Bodegraven, A., et al. (2015). Microbiota dynamics in paediatric Crohn's disease from active disease upon achieving clinical remission. \textit{J. Crohn's Colitis} S437–S438. doi:10.1093/ect-jc/jcu027.830

Dendrou, C. A., Fugger, L., and Fries, M. A. (2015). Immunopathology of multiple sclerosis. \textit{Nat. Rev. Immunol.} 15, 545–558. doi:10.1038/nri3871

Diaz-Gallo, L.-M., and Martin, J. (2012). Common genes in autoimmune diseases: a link between immune-mediated diseases. \textit{Expert Rev. Clin. Immunol.} 8, 107–109. doi:10.1586/cci.11.90

Dicksee, J., Halfvarson, J., Rosenquist, M., Jarnerot, G., Tysk, C., Apajalaiti, J., et al. (2008). Molecular analysis of the gut microbiota of identical twins with Crohn's disease. \textit{ISME J.} 2, 716–727. doi:10.1038/ismej.2008.37

Distrutti, E., Monaldi, L., Ricci, P., Fiorucci, S., Distrutti, E., Monaldi, L., et al. (2016). Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. \textit{World J. Gastroenterol}. 22, 2219–2241. doi:10.3748/wjg.v22.i22.2219

Dollive, S., Peterfreund, G. L., Sherrill-Mix, S., Bittinger, K., Sinha, R., Hoffmann, C., et al. (2012). A tool kit for quantifying eukaryotic rRNA gene sequences from human microbiome samples. \textit{Genome Biol.} 13:R60. doi:10.1186/gb-2012-13-7-r60

Duncan, S. H., Hold, G. L., Barcenilla, A., Stewart, C. S., and Flint, H. J. (2002). \textit{Roseburia intestinalis} sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. \textit{Int. J. Syst. Evol. Microbiol.} 52, 1615–1620. doi:10.1099/ijs.0.02143-0

Ebringer, R., Cooke, D., Cawdell, D. R., Cowling, P., and Ebringer, A. (1977). Ankylosing spondylitis: \textit{Klebsiella} and \textit{HLA} B27. \textit{Rheumatol. Rehabil.} 16, 190–196. doi:10.1093/rheumatology/16.3.190

Eppinga, H., Weiland, C. J. S., Bing Thio, H., van der Woude, C. J., Nijsten, T. E. C., Peppelenbosch, M. P., et al. (2015). Similar depletion of protective \textit{Fusobacterium} in patients with inflammatory bowel disease, but not in Hidradenitis suppurativa. \textit{J. Crohn's Colitis} doi:10.1093/ect-jc/jw070 [Epub ahead of print]

Ezendam, J., De Klerk, A., Gremer, E. R., and Van Loveren, H. (2008). Effects of Bifidobacterium animals administered during lactation on allergic and autoimmune responses in rodents. \textit{Clin. Exp. Immunol.} 154, 424–431. doi:10.1111/j.1365-2249.2008.03788.x

Ezendam, J., and van Loveren, H. (2008). \textit{Lactobacillus casei} Striota administered during lactation increases the duration of autoimmunity in rats and enhances lung inflammation in mice. \textit{Br. J. Nutr.} 99, 83–90. doi:10.1017/S0007114507083412

Fahlin, Å., Engstrand, L., Baker, B. S., Powles, A., and Fry, L. (2012). Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. \textit{Arch. Dermatol. Res.} 304, 15–22. doi:10.1007/s00403-011-1189-x

Fahlin, Å., Gjure, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., et al. (2013). The long-term stability of the human gut microbiota. \textit{Science} 341:1237439. doi:10.1126/science.1237439

Fry, L., and Baker, B. S. (2007). Triggering psoriasis: the role of infections and medications. \textit{Clin. Dermatol.} 25, 606–615. doi:10.1016/j.clindermatol.2007.08.015

Gaboriau-Routhiau, V., Rakotobe, S., Remy, E., Lécuru, Y., Maures, L., et al. (2013). The role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. \textit{Immunity} 31, 677–689. doi:10.1016/j.immuni.2009.08.020

Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Dyrberg, T., et al. (2014). The treatment-naïve microbiome in new-onset Crohn's disease. \textit{Cell Host Microbe} 15, 382–392. doi:10.1016/j.chom.2014.02.005

Goldblatt, F., and Neill, S. G. (2013). Clinical aspects of autoimmune rheumatic diseases. \textit{Lancet} 382, 797–808. doi:10.1016/S0140-6736(13)61499-3
Gordon, H., and Harbord, M. (2014). A patient with severe Crohn’s colitis responds to faecal microbiota transplantation. J. Crohns Colitis 8, 256–257. doi: 10.1016/j.crohns.2013.10.007

Guerrero, C., Tort, J., Perez, J., Andrés, M., and Espejo, E. (2015). Rhodococcus equi infection in a patient with Crohn’s disease treated with infliximab. J. Infect. 70, 689–690. doi: 10.1016/j.jinf.2014.12.008

Gullberg, R. (1978). Possible role of alterations of the intestinal flora in Rheumatoid Arthritis. Rheumatol. Rehabil. XVII, Suppl. 5–10. doi: 10.1093/rheumatology/xvii.suppl.5

Hafer, A., Krämer, S., Duncker, S., Krüger, M., Manns, M. P., and Bischoff, S. C. (2007). Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 7:36. doi: 10.1186/1471-230X-7-36

Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Barreiro-De Acosta, M., Boberg, K. M., et al. (2016). The First European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J. Crohns Colitis 10, 239–254. doi: 10.1093/ecto-jcc/jcv213

Hevia, A., Milani, C., López, P., Cuervo, A., Arboleya, S., Duranti, S., et al. (2014). Intestinal dysbiosis associated with systemic lupus erythematosus. MBio 5:e1548-14. doi: 10.1128/MBio.01548-14

Hoffmann, C., Dollive, S., Grunberg, S., Chen, J., Li, H., Wu, G. D., et al. (2013). Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS ONE 8:e66019. doi: 10.1371/journal.pone.0066019

Holmøy, T., and Torkildsen, Ø. (2016). Can vitamin D reduce inflammation in patients with inflammatory bowel disease? A systematic review and meta-analysis. Inflamm. Bowel Dis. 70, 689–690. doi: 10.1016/j.ibd.2016.01.008

Kobayashi, T., Kato, I., Nanno, M., Shida, K., Shibuya, K., Matsuoka, Y., et al. (2010). Oral administration of probiotic bacteria, Lactobacillus casei and Bifidobacterium breve, does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis. Immunopharmacol. Immunotoxicol. 32, 116–124. doi: 10.1080/08929990320716

Kohashi, O., Kohashi, Y., Takahashi, H., Ozawa, A., and Shigematsu, N. (1985). Reverse effect of gram-positive bacteria vs. gram-negative bacteria on adjuvant-induced arthritis in germfree rats. Microbiol. Immunol. 29, 487–497. doi: 10.1111/j.1348-0421.1985.tb08051.x

Kohashi, O., Kohashi, Y., Takahashi, H., Ozawa, A., and Shigematsu, N. (1986). Suppressive effect of Escherichia coli on adjuvant-induced arthritis in germ-free rats. Arthritis Rheum. 29, 547–553. doi: 10.1002/art.1780290413

Kohashi, O., Kuwata, J., Umehara, K., Uemura, F., Takahashi, T., and Ozawa, A. (1979). Susceptibility to adjuvant-induced arthritis among germfree, specific-pathogen-free, and conventional rats. Infect. Immun. 26, 791–794

Kolho, K.-L., Korpela, K., Jaakkola, T., Pichai, M. V. A., Zoetendal, E. G., and Salonen, A. (2015). Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am. J. Gastroenterol. 110, 921–930. doi: 10.1038/ajg.2015.149

Kushkeych, V. I (2014). Etiological role of sulfate-reducing bacteria in the development of inflammatory bowel diseases and Ulcerative Colitis. Am. J. Infect. Dis. Microbiol. 2, 63–73. doi: 10.12691/ajidm-2-3-5

Kwon, H. K., Kim, C. G., Kim, Y., Hwang, W., Jash, A., Sahoo, A., et al. (2013). Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin. Immunol. 146, 217–227. doi: 10.1016/j.clim.2013.01.001

Larcombe, S., Hutton, M. L., and Lytras, D. (2016). Involvement of bacteria other than clostridium difficile in antibiotic-associated diarrhea. Trends Microbiol. 24, 463–476. doi: 10.1016/j.tim.2016.02.001

Larsen, N., Vogensen, F. K., Van Den Berg, F. W. J., Nielsen, D. S., Andersen, A. S., Pedersen, B. K., et al. (2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5:e9085. doi: 10.1371/journal.pone.0009085

Lavasanis, S., Dzhambazov, B., Nouri, M., Fåk, F., Buske, S., Molin, G., et al. (2010). A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE 5:e9009. doi: 10.1371/journal.pone.0009009

Lee, Y. K., Menezes, J. S., Umesaki, Y., and Mazmanian, S. K. (2011). Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl.), 4615–4622. doi: 10.1073/pnas.100082107

Lepage, P., Colombet, J., Marteau, P., Sime-Ngando, T., Dore, J., and Leclerc, M. (2008). Dysbiosis in inflammatory bowel disease: a role for bacteriophages? Gut 57, 424–425. doi: 10.1136/gut.2007.134668

Lepage, P., Hölsér, R., Spelmann, M. E., Rehman, A., Zvirbliene, A., Begun, A., et al. (2011). Twin study indicates loss of interaction between microbiota and MHC-B27 and human HLA-B27. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl.), 4615–4622. doi: 10.1073/pnas.1011111108

Li, G., Yang, M., Zhou, K., Zhang, L., Tian, L., Ly, S., et al. (2015). Diversity of duodenal and rectal microbiota in biopsy tissues and luminal contents in healthy volunteers. J. Microbiol. Biotechnol. 25, 1136–1145. doi: 10.4041/imib.1412.12047

Lim, P., Bach, M., Asquith, M., Lee, A. Y., Akileswaran, L., Stauffer, P., et al. (2014). HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLoS ONE 9:e105684. doi: 10.1371/journal.pone.0105684

Lindsay, J. O., Whelan, K., Stagg, A. J., Gobin, P., Al-Hassi, H. O., Rayment, N., et al. (2006). Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55, 348–355. doi: 10.1136/gut.2005.074971

Liu, X., Zou, Q., Zeng, B., Fang, Y., and Wei, H. (2013). Analysis of fecal Bifidobacterium community structure in patients with early rheumatoid arthritis. Curr. Microbiol. 67, 170–176. doi: 10.1007/s00284-013-0338-1
Lopez-Siles, M., Martinez-Medina, M., Abella, C., Busquets, D., Sabat-Mir, M., Duncan, S. H., et al. (2015). Mucosa-associated Faecalibacterium prausnitzii phytophile richness is reduced in patients with inflammatory bowel disease. Appl. Environ. Microbiol. 81, 7582–7592. doi: 10.1128/AEM.02069-15

Lutgens, M., Vermeire, S., Van Oijen, M., Vleggaar, F., Siersma, P., van Assche, G., et al. (2015). A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 13, 148.e1–154.e1. doi: 10.1016/j.cgh.2014.06.032

Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijis, I., Eeckhaut, V., et al. (2014). A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275–1283. doi: 10.1136/gutjnl-2013-304833

Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., et al. (2006). Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205–211. doi: 10.1136/gut.2005.073817

Manson, L. S., and Coldhalb, H. (1965). The intestinal flora in patients with bronchial asthma and rheumatoid arthritis. Allergy 20, 94–104. doi: 10.1111/j.1398-9995.1965.tb03360.x

Marín-Jiménez, I., García Sánchez, V., Gisbert, J., Lázaro Pérez Calle, J., Luján, M., Gordillo Ábalos, J., et al. (2014). Prevalence of different immune mediated inflammatory diseases in patients with inflammatory bowel disease. AQUILES study. Gastroenterol. Hepatol. 37, 495–502. doi: 10.1016/S1873-9946(13)60647-9

Martinez-Medina, M., and García-Gil, L. (2014). Escherichia coli in chronic inflammatory diseases: an update on adherent invasive Escherichia coli pathogenicity. World J. Gastroenterol. 21, 5–227. doi: 10.4292/wjg.v5.i3.213

McInnes, I. B., and Schett, G. (2011). The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219. doi: 10.1056/NEJMra1004965

Metz, L. M., Li, D., Traboulsee, A., Myles, M. L., Duquette, P., Godin, J., et al. (2009). Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult. Scler. 15, 1183–1194. doi: 10.1177/1352458509106779

Mielants, H., Veys, E., Goemaere, S., Goethals, K., Cuvelier, C., and De Vos, M. (2013). Reduced diversity of faecal microbiota in Crohn's disease revealed in colorectal carcinoma tissue and patient prognosis. Gut 62, 2205–2219. doi: 10.1056/NEJMra1004965

Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onisch, C., et al. (2006). Reduced diversity of faecal microbiota in Crohn's disease revealed in chronic inflammatory bowel disease. Gut 55, 509–511. doi: 10.1136/gut.2005.073817

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001

Mukhopadhyay, I., Hansen, R., Meharg, C., Thomson, J. M., Russell, R. K., Berry, S. H., et al. (2014). The fungal microbiota of de novo paediatric inflammatory bowel disease. Microbes Infect. 17, 304–310. doi: 10.1016/j.micinf.2014.12.001
Sherer, A. B., Kao, J. Y., and Young, V. B. (2015). The gut microbiome in health and disease. *Curr. Opin. Gastroenterol.* 31, 69–75. doi: 10.1097/m.gastro.2014.03.032

Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., et al. (2014). Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* 40, 128–139. doi: 10.1016/j.immuni.2013.12.007

Sinkorova, Z., Capkova, J., Neiderlova, J., Steck, R., Hamm, T. E., Balish, E., et al. (2008). Commensal intestinal bacterial strains trigger ankylosing enthesopathy of the ankle in inbred B10.BR (H-2k) male mice. *Hum. Immunol.* 69, 845–850. doi: 10.1016/j.humimm.2008.08.296

Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-y, M., et al. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic T cell homeostasis. *Science* 341, 569–573. doi: 10.1126/science.1241165

Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humárán, L. G., Gratadoux, J.-J., et al. (2008). *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. U.S.A.* 105, 16731–16736. doi: 10.1073/pnas.0804812105

Somers, E. C., Thomas, S. L., Sneath, L., and Hall, A. J. (2006). Autoimmune diseases co-occurring within individuals and within families. *Epidemiology* 17, 202–217. doi: 10.1097/01.ede.0000193605.93416.d5

Sorrentino, R. (2014). Genetics of autoimmunity: an update. *Immunol. Lett.* 158, 116–119. doi: 10.1016/j.imlet.2013.12.005

Stebbins, S., Munro, K., Simon, M. A., Tannock, G., Highton, J., Harmsen, H., et al. (2002). Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. *Rheumatology (Oxford)* 41, 1395–1401. doi: 10.1093/rheumatology/41.12.1395

Strauss, J., Kaplan, G. G., Beck, P. L., Rioux, K., Panaccione, R., Devlin, N., et al. (2011). Invasive potential of gut mucosa-derived *Faecalibacterium nucleatum* positively correlates with IBD status of the host. *Inflamm. Bowel Dis.* 17, 1971–1978. doi: 10.1002/ibd.21606

Svartz, N. (1948). The treatment of rheumatic polyarthritis with acid azo compounds. *Rheumatism* 4, 180–185.

Tap, J., Mondot, S., Levenez, F., Pelletier, E., Caron, C., Furet, J.-P., et al. (2009). Towards the human intestinal microbiota phylogenetic core. *Environ. Microbiol.* 11, 2574–2584. doi: 10.1111/j.1462-2920.2009.01982.x

Taurog, J. D., Richardson, J. A., Croft, J. T., Simmons, W. A., Zhou, M., Fernández-Suero, J. L., et al. (1994). The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J. Exp. Med.* 180, 2359–2364. doi: 10.1084/jem.180.8.2359

Thomas, G. P., and Brown, M. A. (2010). Genetics and genomics of ankylosing spondylitis. *Immunol. Rev.* 233, 162–180. doi: 10.1111/j.1600-0852.2009.00852.x

Tilley, B. C., Alarcon, G. S., Heyse, S. P., Tremthen, D. E., Neuner, R., Kaplan, D. A., et al. (1995). Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. *Ann. Intern. Med.* 122, 81–89. doi: 10.7326/0003-4819-122-2-199501150-00001

Tremlett, H., Fadros, D., Farquhi, A., Hart, J., Roalstad, S., Graves, J., et al. (2016a). Associations between immune markers and gut microbiota in pediatric multiple sclerosis and controls (S29.008). *Neurology* 86, S29.008.

Tremlett, H., Fadros, D., Lynch, S., Hart, K., Graves, J., Lulu, S., et al. (2015). Gut microbiome in early pediatric multiple sclerosis: a case-control study (*P4.027*). *Neurology* 84.

Tremlett, H., Fadros, D. W., Faruqui, A. A., Hart, J., Roalstad, S., Graves, J., et al. (2016b). Gut microbiota composition and relapse risk in pediatric MS: a pilot study. *J. Neurol. Sci.* 363, 153–157. doi: 10.1016/j.jns.2016.02.042

Vaahtovuo, J., Munukka, E., Kerolampi, M., Laruikainen, R., and Toivanen, P. (2008). Fecal microbiota in early rheumatoid arthritis. *J. Rheumatol.* 35, 1500–1505.

Vaghef-Mehrabany, E., Alipour, B., Homayouni-Rad, A., Sharif, S.-K. K., Asghari-Jafarabadi, M., and Zavvari, S. (2014). Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. *Nutrition* 30, 430–435. doi: 10.1016/j.nut.2013.09.007

Wheeler, D. A., May, B., Long, J. M., Thompson, W. Y., Sodergren, E. J., et al. (2004). The metazoan root of the vertebrates. *Science* 304, 179–187. doi: 10.1126/science.1098241

Westphal, M., Dellweg, G., et al. (1981). *Escherichia coli* and *Salmonella typhimurium* : a genetic and biochemical comparison. In *Bacteriological Reviews* , vol. 45, no. 1. American Society for Microbiology.
Valdimarsson, H., Baker, B. S., Jonsdottir, I., Powles, A., and Fry, L. (1995). Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? *Immunol. Today* 16, 145–149. doi: 10.1016/0167-5699(95)80312-4

van den Broek, M. F., van Bruggen, M. C., Koopman, J. P., Hazenberg, M. P., and van den Berg, W. B. (1992). Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rats. *Clin. Exp. Immunol.* 88, 313–317. doi: 10.1111/j.1365-2249.1992.tb03079.x

van der Meulen, T. A., Harmsen, H. J. M., Bootsma, H., Spijkervet, F. K. L., Kroese, F. G. M., and Vissink, A. (2016). The microbiome-systemic diseases connection. *Oral Dis.* doi: 10.1111/odi.12472 [Epub ahead of print].

van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., et al. (2013). Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N. Engl. J. Med.* 368, 407–415. doi: 10.1056/NEJMoa1205037

Vanaclocha, F., Crespo-Erchiga, V., Jiménez-Puya, R., Puig, L., Sánchez-Carazo, J. L., Ferrán, M., et al. (2015). Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study. *Actas Dermosifiliogr.* 106, 35–43. doi: 10.1016/j.ad.2014.06.003

Wagner, J., Maksimovic, J., Farries, G., Sim, W. H., Bishop, R. F., Cameron, D. J., et al. (2013). Bacteriophages in gut samples from pediatric Crohn's disease patients. *Inflamm. Bowel Dis.* 19, 1598–1608. doi: 10.1097/MIB.0b013e318292477c

Wang, Y., and Kasper, L. H. (2014). The role of microbiome in central nervous system disorders. *Brain. Behav. Immun.* 38, 1–12. doi: 10.1016/j.bbi.2013.12.015

Wexler, H. M. (2007). Bacteroides: the good, the bad, and the nitty-gritty. *Clin. Microbiol. Rev.* 20, 593–621. doi: 10.1128/CMR.00008-07

Wu, X., Chen, H., and Xu, H. (2015). The genomic landscape of human immune-mediated diseases. *J. Hum. Genet.* 60, 673–681. doi: 10.1038/jhg.2015.99

Zhang, B. J., Markovic-plese, S., Lacet, B., Raus, J., Weiner, H. L., and Hailer, D. A. (1994). Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. *J. Exp. Med.* 179, 973–984. doi: 10.1084/jem.179.3.973

Zhang, H., Liao, X., Sparks, J. B., and Luo, X. M. (2014). Dynamics of gut microbiota in autoimmune lupus. *Appl. Environ. Microbiol.* 80, 7551–7560. doi: 10.1128/AEM.02676-14

Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D., et al. (2015). The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat. Med.* 21, 895–905. doi: 10.1038/nm.3914

Zitomersky, N. L., Atkinson, B. J., Franklin, S. W., Mitchell, P. D., Snapper, S. B., Comstock, L. E., et al. (2013). Characterization of adherent bacteroides from intestinal biopsies of children and young adults with inflammatory bowel disease. *PLoS ONE* 8:e63686. doi: 10.1371/journal.pone.0063686

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

CB has served on advisory boards of AbbVie Canada, Janssen Canada, Pfizer Canada, Shire Canada, Takeda Canada, Cubist Pharmaceuticals, and has consulted to Mylan Pharmaceuticals. He has received unrestricted educational grants from AbbVie Canada, Janssen Canada, Shire Canada, and Takeda Canada. He is on speakers bureau of AbbVie Canada and Shire Canada.

Copyright © 2016 Forbes, Van Domselaar and Bernstein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.